-
New Class of Migraine Drug Creates Four-Way Pharma Development Race
Thursday, September 6, 2018 - 3:58pm | 1272Migraines — a neurological condition often characterized by intense, debilitating headaches — can last anywhere from four to 72 hours, affecting a patient's quality of life. Until recently, there was no specific treatment for migraine, although symptom-alleviating options...
-
Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates
Tuesday, May 1, 2018 - 3:39pm | 1196Even amid the thick of earnings season, biotech stocks sway to the din produced by catalytic events, which include PDUFA action dates. Here's a rundown on the PDUFA dates scheduled for the month of May. 1. Will Second Time Be Charm For Portola? Company: Portola Pharmaceuticals Inc (...